Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 31;20(1):2309701.
doi: 10.1080/21645515.2024.2309701. Epub 2024 Feb 1.

Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma

Maria Cristina Pirosa  1   2   3 , Anastasios Stathis  1   3 , Emanuele Zucca  1   2   3
Affiliations

Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma

Maria Cristina Pirosa et al. Hum Vaccin Immunother. .

Abstract

Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) require additional treatments, especially those not eligible or not responding to high dose cytotoxic chemotherapy and stem cell transplantation. Over the last few years, several new treatments have been developed and approved for these patients, among them of particular relevance are those targeting CD19. Tafasitamab is a humanized monoclonal antibody targeting CD19, composed of a modified fragment crystallizable (Fc) region engineered with higher affinity for Fc gamma receptors (FcγR) receptors, leading to increased cytotoxicity through natural killer cells and macrophages (antibody-dependent cellular cytotoxicity and antibody-dependent cell-mediated phagocytosis). In this product review, we will discuss its mechanism of action, safety profile and efficacy results from clinical trials that led to its approval in combination with lenalidomide for patients with R/R DLBCL ineligible for high-dose chemotherapy and autologous transplantation.

Keywords: Anti CD-19 agent; DLBCL; Tafasitamab; relapsed-refractory disease; monoclonal antibodies.

PubMed Disclaimer

Conflict of interest statement

MCP: travel grant from BeiGene, Institutional funding for clinical trial Incyte; AS: Institutional funding for clinical trials: Abbvie; ADC Therapeutics; Amgen, Astra Zeneca; Bayer; Cellestia; Incyte, Loxo Oncology; Merck MSD; Novartis; Pfizer; Philogen; Roche; Consultant/expert testimony/advisory board: Debiopharm, Janssen, AstraZeneca, Incyte, Eli Lilly, Novartis, Roche, Loxo Oncology. Travel grant: Incyte; Astra Zeneca; EZ: honoraria from AstraZeneca, BeiGene, Celgene, Incyte, Janssen, Merck, Roche AbbVie, Miltenyi Biomedicine, Celltrion HealthCare, Kite, A Gilead Company.

References

    1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. May 19 2016;127(20):2375–7. doi:10.1182/blood-2016-01-643569. - DOI - PMC - PubMed
    1. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018. May;24(5):679–690. doi:10.1038/s41591-018-0016-8. - DOI - PMC - PubMed
    1. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, et al. Genetics and Pathogenesis of diffuse large B-Cell Lymphoma. N Engl J Med. Apr 12 2018;378(15):1396–1407. doi:10.1056/NEJMoa1801445. - DOI - PMC - PubMed
    1. Iacoboni G, Zucca E, Ghielmini M, Stathis A.. Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review. Ann Oncol. May 1 2018;29(5):1120–1129. doi:10.1093/annonc/mdy113. - DOI - PubMed
    1. Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, et al. Polatuzumab vedotin in previously untreated diffuse large B-Cell lymphoma. N Engl J Med. Jan 27 2022;386(4):351–363. doi:10.1056/NEJMoa2115304. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources